Drug Profile
Adalimumab biosimilar - Axxo
Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator AXXO
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 27 Sep 2013 Investigation in Psoriatic arthritis in Germany (SC)
- 27 Sep 2013 Investigation in Rheumatoid arthritis in Germany (SC)